Presented at #ATS2025:
In the VERITAS trial, biopsy of indeterminate pulmonary lesions with navigational bronchoscopy was noninferior to that with transthoracic needle biopsy and led to fewer complications. Full trial results: https://t.co/UHpriqNTHf
Editorial: Biopsy of Peripheral Lung Nodules — Inside Out or Outside In? https://t.co/u1ewrtkmGC
@atscommunity
Thrilled to see VERITAS out in @NEJM today. Nav bronch noninferior to transthoracic needle biopsy for lung nodules 10-30 mm. Nav bronch made an accurate diagnosis in 79% vs. 73% for TTNB, with pneumothorax requiring chest tube and/or hospitalization in 1% vs. 12%, respectively.
Big shoutout to the Thoracic Oncology and Chest Procedure Network Leadership for setting an agenda in research for 2025. We are excited to participate! Also shoutout to @RobJLentz and Jeff Thiboutot for excellent presentations and to Jeff for being the Rising Star. Well deserved!
Newly identified unilateral pleural effusion in a HOSPITALIZED patient - dyspnea is present. You favor this being an exudative effusion. What is your INITIAL drainage strategy if anechoic on the US? @AAB_IP @MaldonadoFabien @dfellerk@udit_chaddha@Re_innervated
The Pleural Disease Section reviews current guidelines from both CHEST and BTS for optimal management of primary spontaneous and secondary spontaneous pneumothorax. Read more: https://t.co/sAs8HbifYl
Kaele M. Leonard, MD, and Robert J. Lentz, MD, join CHEST® Journal Podcast Moderator, Dominique Pepper, MD, to discuss whether a conservative diagnostic yield definition may represent a useful outcome for future studies of diagnostic utility. Listen now: https://t.co/Z5Pl2g4hDv
4 ways I feel interventional pulmonologists succumb to the hammer-nail mindset and demean ourselves
🛑Sampling nodules cause ‘we can’
🛑Valves for everyone
🛑Treating imaging and not pts, with pleural dz
🛑Stenting airways that lead to no physiological gain
@AAB_IP@wabipconnect